On April 1, an FDA advisory panel gave a thumbs up to MannKind Corp.’s inhaled insulin Afrezza, which would be used specifically for meal-time doses to prevent post-prandial blood sugar spikes and would be quick and easy to dose via a tiny inhaler device that fits in the palm of your hand (and looks like a whistle).

Read more